Celator Pharmaceuticals

Celator Pharmaceuticals was an oncology biopharmaceutical company founded in 1999 that developed combination cancer therapies using its CombiPlex drug-delivery platform. Its lead program, VYXEOS (CPX-351), combines cytarabine and daunorubicin for acute myeloid leukemia. Based in Ewing, New Jersey before its acquisition, Celator became a subsidiary of Jazz Pharmaceuticals in July 2016.